Hartford Funds Management Co LLC Takes $208,000 Position in Danaher Co. (NYSE:DHR)

Hartford Funds Management Co LLC acquired a new position in Danaher Co. (NYSE:DHRGet Rating) during the 3rd quarter, according to its most recent filing with the SEC. The fund acquired 802 shares of the conglomerate’s stock, valued at approximately $208,000. Danaher makes up about 0.0% of Hartford Funds Management Co LLC’s holdings, making the stock its 29th largest holding.

A number of other large investors have also recently added to or reduced their stakes in the business. Steward Financial Group LLC lifted its holdings in shares of Danaher by 330.4% in the second quarter. Steward Financial Group LLC now owns 99 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 76 shares in the last quarter. Goodman Advisory Group LLC acquired a new stake in Danaher during the 2nd quarter valued at $27,000. Moisand Fitzgerald Tamayo LLC increased its position in Danaher by 5,850.0% during the third quarter. Moisand Fitzgerald Tamayo LLC now owns 119 shares of the conglomerate’s stock worth $31,000 after buying an additional 117 shares in the last quarter. Investors Asset Management of Georgia Inc. GA ADV acquired a new position in Danaher in the 2nd quarter valued at about $32,000. Finally, WFA of San Diego LLC acquired a new position in shares of Danaher in the second quarter valued at approximately $35,000. 77.26% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on DHR shares. Credit Suisse Group downgraded shares of Danaher from an “outperform” rating to a “neutral” rating and cut their price target for the stock from $315.00 to $300.00 in a research note on Thursday, January 5th. Cowen lowered their price objective on shares of Danaher from $340.00 to $320.00 in a research report on Wednesday. JPMorgan Chase & Co. dropped their price objective on Danaher from $350.00 to $315.00 and set an “overweight” rating on the stock in a report on Friday, October 21st. Barclays upped their price objective on Danaher from $277.00 to $290.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Benchmark downgraded shares of Danaher from a “buy” rating to a “hold” rating and set a $325.00 price objective for the company. in a research report on Monday, October 24th. Three analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $310.29.

Insider Buying and Selling at Danaher

In other news, CFO Matthew Mcgrew sold 18,935 shares of Danaher stock in a transaction on Friday, November 11th. The shares were sold at an average price of $274.72, for a total transaction of $5,201,823.20. Following the transaction, the chief financial officer now directly owns 29,634 shares of the company’s stock, valued at $8,141,052.48. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, EVP Joakim Weidemanis sold 9,508 shares of the business’s stock in a transaction on Monday, November 28th. The shares were sold at an average price of $266.60, for a total value of $2,534,832.80. Following the sale, the executive vice president now directly owns 71,498 shares of the company’s stock, valued at approximately $19,061,366.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Matthew Mcgrew sold 18,935 shares of Danaher stock in a transaction dated Friday, November 11th. The shares were sold at an average price of $274.72, for a total value of $5,201,823.20. Following the completion of the sale, the chief financial officer now directly owns 29,634 shares in the company, valued at approximately $8,141,052.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 38,538 shares of company stock valued at $10,424,284. 11.20% of the stock is currently owned by insiders.

Danaher Price Performance

Danaher stock traded down $7.09 on Wednesday, reaching $264.49. The company’s stock had a trading volume of 1,618,052 shares, compared to its average volume of 2,813,922. Danaher Co. has a twelve month low of $233.71 and a twelve month high of $303.82. The company has a market cap of $192.54 billion, a price-to-earnings ratio of 30.01, a PEG ratio of 2.23 and a beta of 0.82. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.38 and a current ratio of 1.78. The business’s fifty day moving average price is $266.13 and its 200 day moving average price is $268.98.

Danaher (NYSE:DHRGet Rating) last announced its earnings results on Tuesday, January 24th. The conglomerate reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.46 by $0.41. Danaher had a net margin of 21.65% and a return on equity of 18.33%. The company had revenue of $8.37 billion during the quarter, compared to the consensus estimate of $7.90 billion. During the same period in the previous year, the firm posted $2.69 earnings per share. The company’s revenue was up 2.7% on a year-over-year basis. Equities analysts expect that Danaher Co. will post 10.55 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Friday, December 30th will be issued a $0.25 dividend. The ex-dividend date of this dividend is Thursday, December 29th. This represents a $1.00 annualized dividend and a yield of 0.38%. Danaher’s dividend payout ratio is currently 11.05%.

Danaher Profile

(Get Rating)

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHRGet Rating).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.